Healius Limited (AU:HLS)
ASX:HLS
Want to see AU:HLS full AI Analyst Report?
HLS Stock Chart & Stats
AU$0.54
-AU$0.02(-1.03%)
At close: 4:00 PM EST
AU$0.54
-AU$0.02(-1.03%)
Day’s Range― - ―
52-Week RangeAU$0.49 - AU$1.64
Previous CloseN/A
Volume575.57K
Average Volume (3M)2.94M
Market Cap
AU$384.86M
Enterprise ValueAU$2.00B
Total Cash (Recent Filing)AU$51.60M
Total Debt (Recent Filing)AU$1.66B
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 26, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding726,155,800
10 Day Avg. Volume3,249,015
30 Day Avg. Volume2,941,962
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.26
Price to Sales (P/S)0.11
P/FCF Ratio0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside38.27% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering6
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$1.40B
Bulls Say, Bears Say
Bulls Say
Operating Cash GenerationHealius reports positive operating cash flow versus net income, showing the business still generates cash from core operations. Sustained cash generation supports working capital, funds near-term restructuring or capital needs, and reduces immediate reliance on external financing over months.
Scale Across DiagnosticsHealius’s integrated pathology and imaging footprint provides diversified fee-for-service revenue from GPs, specialists and hospitals. The scale of labs and imaging sites creates durable operational leverage: as referrals and volumes recover, margins and cash conversion can sustainably improve.
Relatively Stable Equity BaseBalance-sheet commentary notes a relatively stable equity ratio despite strain, implying retained asset coverage and a buffer against shocks. A stable equity base preserves borrowing capacity and allows management time to execute turnaround or refinancing without immediate equity erosion.
Bears Say
Declining Revenue TrendMaterial revenue declines (-12% to -14%) reduce utilization of high‑fixed‑cost labs and imaging assets, squeezing unit economics and operating leverage. Persistent lower volumes weaken pricing leverage, threaten contract renewals, and make margin recovery slower, pressuring results over the next several quarters.
Negative ProfitabilityA negative net margin and collapsing EPS indicate the company is not covering costs from operations, eroding retained earnings and limiting reinvestment. Sustained losses constrain strategic choices, impair ability to rebuild margins, and increase reliance on cash or capital markets for funding.
High Financial LeverageElevated debt-to-equity (1.55) raises refinancing and interest-rate risk and constrains strategic flexibility. High leverage amplifies earnings volatility, limits capacity for M&A or capex, and increases the importance of consistent cash generation to meet obligations in the coming months.
Healius Limited News
HLS FAQ
What was Healius Limited’s price range in the past 12 months?
Healius Limited lowest share price was AU$0.49 and its highest was AU$1.64 in the past 12 months.
What is Healius Limited’s market cap?
Healius Limited’s market cap is AU$384.86M.
When is Healius Limited’s upcoming earnings report date?
Healius Limited’s upcoming earnings report date is Aug 26, 2026 which is in 121 days.
How were Healius Limited’s earnings last quarter?
Healius Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.015 earnings per share for the quarter, missing the consensus estimate of -AU$0.001 by -AU$0.014.
Is Healius Limited overvalued?
According to Wall Street analysts Healius Limited’s price is currently Undervalued.
Does Healius Limited pay dividends?
Healius Limited pays a Notavailable dividend of AU$0.635 which represents an annual dividend yield of N/A. See more information on Healius Limited dividends here
What is Healius Limited’s EPS estimate?
Healius Limited’s EPS estimate is 0.03.
How many shares outstanding does Healius Limited have?
Healius Limited has 726,155,800 shares outstanding.
What happened to Healius Limited’s price movement after its last earnings report?
Healius Limited reported an EPS of -AU$0.015 in its last earnings report, missing expectations of -AU$0.001. Following the earnings report the stock price went down -6.748%.
Which hedge fund is a major shareholder of Healius Limited?
Currently, no hedge funds are holding shares in AU:HLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healius Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
AU$0.75 (38.27% Upside)
AU$0.75 (38.27% Upside)
Blogger Sentiment
Bullish
AU:HLS Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$107.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.24%
12-Months-Change
Fundamentals
Return on Equity
-29.48%
Trailing 12-Months
Asset Growth
-45.09%
Trailing 12-Months
Company Description
Healius Limited
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. It operates 2,105 pathology sites; 11 day hospital sites; and 134 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
HLS Stock 12 Month Forecast
Average Price Target
AU$0.75
▲(38.27% Upside)
Technical Analysis
Lumos Diagnostics Holdings Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---